• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • LIVE NOW
        Title
        User
        • Sign In
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5637
    • Acute Myelogenous Leukemia 149
    • Bladder Cancer 49
    • Bone Metastases 1
    • Brain Cancer 16
    • Breast Cancer 121
    • Business Management 2
    • Cervical Cancer 2
    • Chronic Lymphocytic Leukemia 156
    • Chronic Myelogenous Leukemia 21
    • Colorectal Cancer 75
    • Gastrointestinal Cancer 70
    • General 246
    • Head and Neck Cancers 34
    • Hematologic Malignancies 79
    • Hodgkin Lymphoma 18
    • Immunotherapy 88
    • Kidney Cancer 364
    • Liver Cancer 11
    • Lymphoma 145
    • Melanoma and Skin Cancer 51
    • Multiple Myeloma 337
    • Myeloproliferative Disease 15
    • News 115
    • Non-Hodgkin Lymphoma 45
    • Non-Small Cell Lung Cancer 267
    • Other 110
    • Ovarian Cancer 10
    • Pancreatic Cancer 54
    • Patient Resources 27
    • Prostate Cancer 148
    • Small Cell Lung Cancer 58
    • Soft Tissue Sarcoma 9
    • Supportive Care 38
    • Testicular Cancer 2
    • Urology 6
    • Uterine Cancer 2

    • About
    • Contact
    H. Jack

    BeaconMedIC

    My videos
    Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
    00:13:27

    Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

    Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter.

    General
    1,201 Views
    11 months ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
    00:08:57

    What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)

    Small Cell Lung Cancer
    925 Views
    11 months ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
    00:09:58

    The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)

    Non-Small Cell Lung Cancer
    689 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
    00:09:53

    Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

    Non-Small Cell Lung Cancer
    614 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
    00:06:38

    The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)

    Non-Small Cell Lung Cancer
    549 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
    00:09:41

    The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)

    Non-Small Cell Lung Cancer
    463 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
    00:04:12

    Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

    Non-Small Cell Lung Cancer
    424 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
    00:08:03

    Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)

    Non-Small Cell Lung Cancer
    222 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)
    00:07:21

    Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)

    Immunotherapy
    259 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
    00:07:18

    IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)

    Small Cell Lung Cancer
    333 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    "Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)
    00:09:08

    "Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)

    Non-Small Cell Lung Cancer
    332 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)
    00:15:36

    Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)

    Non-Small Cell Lung Cancer
    342 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
    00:03:39

    TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)

    Testicular Cancer
    326 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
    00:01:34

    Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)

    Prostate Cancer
    247 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
    00:02:46

    What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)

    Prostate Cancer
    256 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
    00:03:02

    New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)

    Prostate Cancer
    179 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)
    00:02:02

    Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)

    Prostate Cancer
    197 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
    00:01:08

    Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)

    Prostate Cancer
    106 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
    00:02:17

    Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)

    Prostate Cancer
    205 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
    00:02:18

    Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)

    Kidney Cancer
    97 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
    00:03:18

    Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)

    Kidney Cancer
    77 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)
    00:02:06

    Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)

    Kidney Cancer
    57 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)
    00:04:37

    Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)

    Kidney Cancer
    76 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)
    00:02:58

    Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)

    Bladder Cancer
    99 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)
    00:01:57

    Novel Agent Enfortumab, a Nectin-4 Inhibitor, for Transitional Cell Carcinoma of the Bladder: Highlights from ASCO 2018 (BMIC-049)

    Bladder Cancer
    101 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

      Copyright 2019 Medicus Networks, Inc.